Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 8, 2009, Pages 1057-1066

  Banti, Irene ^a   Nencetti, Susanna ^a   Orlandini, Elisabetta ^a   Lapucci, Annalina ^a   Breschi, Maria Cristina ^a   Fogli, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Angiogenesis; Apoptosis; Cytotoxicity; Growth factors; Naphthyridines; Structure activity relationship

Indexed keywords

1,8 NAPHTHYRIDINE DERIVATIVE; CASPASE 3; CASPASE 7; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUOROURACIL; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR; NAPHTHYRIDINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PANCREAS CANCER; SUBSTITUTION REACTION; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; PANCREAS TUMOR; PATHOLOGY; SYNTHESIS; TIME; TOXICITY TESTING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLAST GROWTH FACTORS; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; NAPHTHYRIDINES; PANCREATIC NEOPLASMS; TIME FACTORS; TOXICITY TESTS;

EID: 85047684386     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.08.0010     Document Type: Article

References (22)

1. Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol 2007; 34: 284-294.
2. YangL et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 63: 6815-6824.
3. Rocha-Lima CM. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs 2008; 19: 435-446.
4. Litvinov VP. Chemistry and biological activities of 1,8-naphthyridines. Russ Chem Rev 2004; 73: 637-669.
5. Srivastava S et al. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anticancer Agents Med Chem 2007; 7: 685-709.
6. Tomita K et al. Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3- carboxylic acids as antitumor agents. Part 1. J Med Chem 2002; 45: 5564-5575.
7. Deady L et al. Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridin-(5H)ones. Bioorg Med Chem 2005; 13: 1341-1355.
8. Imperio D et al. Replacement of the lactone moiety on podophyllotoxin and steganacin analogues with a 1,5-disubstituted 1,2,3-triazole via ruthenium-catalyzed click chemistry. Bioorg Med Chem 2007; 15: 6748-6757.
9. Jamart-Gregoire B et al. A new series of tricyclic (aryloximino) propanolamines displaying very high selective beta 2-blocking properties. J Med Chem 1989; 32: 315-320.
10. Ferrarini P et al. Synthesis and β-blocking activity of (E)- and (Z)-iminoethers of 1,8-naphthyridine. Potential antihypertensive agents. Eur J Med Chem 1990; 25: 489-496.
11. Ferrarini P et al. Stereoselective synthesis and β-blocking activity of substituted (E)- and (Z)-4(1H)-[1-(3-alkylamino-2-hydroxypropyl) oximino]-2,3-dihydro-1,8-naphthyridine. Potential antihypertensive agents. Eur J Med Chem 1997; 32: 955-963.
12. Saccomanni G et al. Synthesis and beta-blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3- dihydrothiopyrano[2,3-b]pyridine: identification of beta 3-antagonists. Bioorg Med Chem 2003; 11: 4921-4931.
13. Ferrarini P et al. Synthesis and beta-blocking activity of (R,S)-(E)-oximeethers of 2,3-dihydro-1,8-naphthyridine and 2,3- dihydrothiopyrano[2,3-b]pyridine: potential antihypertensive agents - part IX. Eur J Med Chem 2000; 35: 815-826.
14. Neoptolemos J et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
15. Shi X et al. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 354-362.
16. Yamanaka Y et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993; 53: 5289-5296.
17. Douziech N et al. Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. Endocrine 1998; 9: 171-183.
18. Kleeff J et al. Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors. Cancer Gene Ther 2002; 9: 522-532.
19. Bilodeau M et al. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett 2008; 18: 3178-3182.
20. Hayashi H et al. Down-regulation of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling. Genes Cells 2008; 13: 941-947.
21. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
22. Zhong H. Bowen JP. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature. Curr Med Chem 2006; 13: 849-862.